Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 14/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
| ▸ | TSHR | P16473 | 3/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.80 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8240684 | 1.00 | ADCY1 (0.80) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL11118724 | 1.00 | ADCY1 (0.80) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL30763213 | 0.94 | ADCY1 (0.87) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL11542815 | 0.94 | ADCY1 (0.87) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL8640465 | 0.91 | ADCY1 (0.76) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL8500754 | 0.90 | ADCY1 (0.82) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL11538072 | 0.90 | ADCY1 (0.77) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL9301783 | 0.90 | ADCY1 (0.82) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL8500908 | 0.90 | ADCY1 (0.82) | ADCY1MAPK1CYP3A4TSHRNR1I2 | |
| SCHEMBL9631043 | 0.90 | ADCY1 (0.79) | ADCY1MAPK1CYP3A4TSHRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119564664-A | Application of isoforskolin in preparing medicament for treating diabetic cardiomyopathy | 昆明医科大学第一附属医院(云南省皮肤病医院) | 2025-03-07 | — | — | CN | claimed |
| CN-119386003-A | Application of isoforskolin in preparation of atherosclerosis-inhibiting drugs | 昆明医科大学第一附属医院(云南省皮肤病医院) | 2025-02-07 | — | — | CN | claimed |
| CN-118777484-A | Different from coleus forskohlii medicinal material method for measuring forskolin | 湖北福人药业股份有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-20240148686-A1 | PHARMACEUTICAL COMPOSITION OF FORSKOLIN-ISOFORSKOLIN AND PENTACYCLIC TRITERPENOID COMPOUND, AND APPLICATION THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2024-05-09 | — | — | US | claimed |
| CN-114814006-B | Method for measuring content of chemical components in patchouli leaf | 天津中医药大学 | 2023-06-06 | — | — | CN | claimed |
| CN-115414348-A | Application of forskolin and derivatives thereof in preparation of medicine for treating psoriasis | 昆明医科大学 | 2022-12-02 | — | — | CN | claimed |
| CN-113116955-B | Pharmaceutical composition containing plant extracts and application thereof | 中国药科大学 | 2022-10-04 | — | — | CN | claimed |
| CN-113244405-B | Pharmaceutical composition of forskolin/isoforskolin and pentacyclic triterpenoid and application thereof | 中国药科大学 | 2022-06-21 | — | — | CN | claimed |
| US-4782082-A | BRONCHODILATORS, ANTIHISTAMINES | SCHERING CORPORATION (US) | 1988-11-01 | — | — | US | claimed |
| EP-0116713-A1 | Novel labdane derivatives, process for the preparation thereof, and pharmaceutical compositions containing labdane derivatives | SCHERING CORPORATION (US) | 1984-08-29 | — | — | EP | claimed |
| CN-121698842-A | Preparation method of 6-acetyl forskolin | 云南省药物研究所 | 2026-03-20 | — | — | CN | disclosed |
| CN-121698841-A | Preparation method of 1-acetyl isoforskolin | 云南省药物研究所 | 2026-03-20 | — | — | CN | disclosed |
| CN-121698841-A | Preparation method of 1-acetyl isoforskolin | 云南省药物研究所 | 2026-03-20 | — | — | CN | disclosed |
| CN-119564664-A | Application of isoforskolin in preparing medicament for treating diabetic cardiomyopathy | 昆明医科大学第一附属医院(云南省皮肤病医院) | 2025-03-07 | — | — | CN | disclosed |
| CN-119564664-A | Application of isoforskolin in preparing medicament for treating diabetic cardiomyopathy | 昆明医科大学第一附属医院(云南省皮肤病医院) | 2025-03-07 | — | — | CN | disclosed |
| US-11234957-B2 | Process for preparing water soluble forskolin | SciPharm S.à.r.l (LU) | 2022-02-01 | — | — | US | disclosed |
| US-20210220322-A1 | Disease Modifying Methods For Treating Neurodegenerative Diseases Using Nootropic Agents | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO | 2021-07-22 | — | — | US | disclosed |
| US-20080226571-A1 | Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin | MAJEED MUHAMMED | 2008-09-18 | — | — | US | disclosed |
| US-20080226571-A1 | Compositions and methods to effect enhanced photoprotection against UV A and UV B induced damage of human skin | MAJEED MUHAMMED | 2008-09-18 | — | — | US | disclosed |
| EP-0116713-A1 | Novel labdane derivatives, process for the preparation thereof, and pharmaceutical compositions containing labdane derivatives | SCHERING CORPORATION (US) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148686-A1 | PHARMACEUTICAL COMPOSITION OF FORSKOLIN-ISOFORSKOLIN AND PENTACYCLIC TRITERPENOID COMPOUND, AND APPLICATION THEREOF | CYP11B2, PRKAR2B, GPR119 | ADCY1 568/4885MAPK1 1188/4885CYP3A4 1532/4885 |
| US-20210220322-A1 | Disease Modifying Methods For Treating Neurodegenerative Diseases Using Nootropic Agents | INA, BDNF, GAP43 | ADCY1 7/4885MAPK1 2804/4885CYP3A4 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.